H.C. Wainwright Sticks to Its Buy Rating for Kezar Life Sciences (KZR)

By Jason Carr

H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Kezar Life Sciences (KZRResearch Report) today and set a price target of $9.00. The company’s shares closed last Monday at $5.16, close to its 52-week low of $2.19.

According to TipRanks.com, Selvaraju is a 5-star analyst with an average return of 17.3% and a 50.1% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Black Diamond Therapeutics, Biospecifics Technologies, and Springworks Therapeutics.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Kezar Life Sciences with a $13.50 average price target.

See today’s analyst top recommended stocks >>

Based on Kezar Life Sciences’ latest earnings release for the quarter ending December 31, the company reported a quarterly GAAP net loss of $9.58 million. In comparison, last year the company had a GAAP net loss of $5.78 million.

Based on the recent corporate insider activity of 19 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of KZR in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Kezar Life Sciences, Inc. is a clinical-stage biotechnology company, which discovers and develops novel small molecule therapeutics to treat autoimmunity and cancer. The firm specializes in the areas of protein degradation and protein secretion to discover & develop novel therapies for the treatment of serious and unmet medical needs. Its product include KZR-616, an immunoproteasome inhibitor, has completed testing in healthy volunteers. The company was founded by John Fowler, Christopher J. Kirk and Jack Taunton on February 20, 2015 and is headquartered in South San Francisco, CA.